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OBJECTIVE—In glucose-sensing neurons, ATP-sensitive K

channels (KATP channels) are thought to translate metabolic
signals into an alteration in neuronal ﬁring rates. Because these
neurons express the Kir6.2/SUR-1 isoform of the KATP channel,
we sought to examine the therapeutic potential of the SUR-1–
selective potassium channel opener (KCO), NN414, to amplify
counterregulatory response to hypoglycemia.
RESEARCH DESIGN AND METHODS—In vivo dose-re-
sponse studies with NN414 delivered intravenously to normal
Sprague-Dawley rats before the induction of controlled hypogly-
cemia were performed. Based on these studies, the potential for
NN414 to restore counterregulatory responses in chronically
cannulated nondiabetic and diabetic BB rats was explored using
the in vivo hyperinsulinemic-hypoglycemic clamp technique.
RESULTS—NN414 delivered systemically ampliﬁed epinephrine
responses during acute hypoglycemia and showed a persisting
effect to amplify the epinephrine response when given 24 h
before the hypoglycemic study. Local delivery of a potassium-
channel blocker to the ventromedial hypothalamus reversed the
effects of systemic NN414. In addition, NN414 ampliﬁed the
epinephrine response to hypoglycemia in both nondiabetic and
diabetic BB rats with defective hormonal counterregulation.
CONCLUSIONS—These studies demonstrate in a variety of
rodent models that systemic delivery of Kir6.2/SUR-1–selective
KCOs enhance the glucose counterregulatory response to insu-
lin-induced hypoglycemia. Future studies in human subjects are
now required to determine their potential as a therapy for
hypoglycemia-associated autonomic failure in type 1 diabetes.
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T
he beneﬁts of lowering average blood glucose
levels in type 1 diabetes to reduce the risk of
long-term microvascular complications are well
established. In clinical practice, the degree to
which this can be achieved is often limited by the in-
creased risk of severe hypoglycemia that accompanies
intensiﬁed glucose-lowering regimens (1,2). Individuals
with type 1 diabetes are, moreover, particularly prone to
develop hypoglycemia because of defects in the normal
compensatory homeostatic defense response. Almost all
individuals with type 1 diabetes fail to release glucagon in
response to hypoglycemia, a defect that appears to relate
to the progressive loss of -cell function (3) and is thought
to arise predominantly through the loss of intraislet insulin
signaling (4). This leaves epinephrine as the major hor-
monal counterregulatory defense against low blood glu-
cose. However, a majority of patients will also develop
additional deﬁciencies in the epinephrine counterregula-
tory response (5). It has now been established in both
rodent (6) and human (7) studies that antecedent expo-
sure to hypoglycemia is a major factor involved in the
genesis of this defect. Several small trials in human
subjects have shown that strict avoidance of hypoglycemia
can improve epinephrine (8,9) and symptomatic (10) re-
sponses during a subsequent hypoglycemic clamp study.
The difﬁculty in achieving strict hypoglycemia avoidance
in both of these trials means that this intervention has not
become part of routine clinical practice. Thus, therapeutic
options designed to limit the impact of hypoglycemia
during intensive insulin therapy remain limited.
The stimulus to epinephrine release during hypoglycemia
is thought to result from activation of specialized glucose-
sensing neurons within the brain (11–14) and periphery (15).
Glucose-sensing neurons use glucose as a signaling molecule
to alter their ﬁring rate and are of two predominant subtypes,
namely, glucose-excited neurons, whose ﬁring rate increases,
and glucose-inhibited neurons, whose ﬁring rate decreases,
as ambient glucose levels rise (16–18). Based largely on data
in rodents, it is currently believed that glucose-sensing neu-
rons react to alterations in extracellular glucose using mech-
anisms similar to those used by the pancreatic -cell, with
glucokinase and the ATP-sensitive K
 channel (KATP)a sk e y
steps in this process (19,20).
KATP channels provide a link between neuronal metab-
olism and membrane potential in many tissues (21,22).
Classical KATP channels comprise two subunits: a receptor
(SUR-1, SUR-2A, or SUR-2B) of sulfonylureas and an
inward-rectiﬁer K
 channel member, Kir6.2 (22,23). Skel-
etal muscle and cardiac KATP channels comprise SUR-2A
and Kir6.2, whereas the pancreatic -cell KATP channel, the
prototype glucose-sensing cell, comprises SUR-1 and
Kir6.2 (21–24). In the pancreas, the KATP channel has been
shown to play a key role in the mechanism by which
-cells regulate insulin release in response to changes in
the glucose to which they are exposed (25,26). KATP
channels have been demonstrated throughout the brain,
including hypothalamic regions thought to be involved in
glucose sensing (27–29). Examination of gene expression
in glucose-sensing neurons using single-cell RT-PCR iden-
tiﬁed mRNA for SUR-1 and Kir6.2 (30). Electrophysiolog-
ical studies of rat (20,31,32) and mouse brain slice
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can stimulate the ﬁring of glucose-excited neurons and can
alter the response of glucose-excited neurons to changes
in ambient glucose levels. In animal models, transgenic
Kir6.2 knockout mice show impaired glucose counterregu-
lation (33), and we have recently shown in vivo that
pharmacological closure of the KATP channel in the
ventromedial hypothalamus (VMH; a key glucose-sensing
region) via direct microinjection of glibenclamide sup-
pressed (34), whereas KATP channel openers (KCOs) am-
pliﬁed, the counterregulatory response to hypoglycemia in
both normal and recurrently hypoglycemic rats (35). In
this later study, the SUR-1–selective KCO NN414, when
microinjected into the VMH, a key brain glucose-sensing
region (36), ampliﬁed hypoglycemic counterregulation at
signiﬁcantly lower concentrations than the nonselective
KCO, diazoxide (35).
Taken together, these data suggest that KATP channels
allow glucose-sensing neurons to translate the metabolic
signal into an alteration in neuronal ﬁring rates and,
moreover, that KCOs may offer a potential therapeutic
option for individuals with type 1 diabetes. In the current
study, this hypothesis is explored in a series of rodent
models. Our data show that systemic administration of a
SUR-1–selective KCO has a consistent effect to amplify the
epinephrine response to controlled hypoglycemia in non-
diabetic and diabetic rats and in those with defective
counterregulation.
RESEARCH DESIGN AND METHODS
Male Sprague-Dawley (n  102; weight 305  4 g [means  SE]) and diabetic
BB rats (n  12; disease duration 2–4 weeks) were housed in the Yale Animal
Resource Center, fed a standard pellet diet (Agway Prolab 3000), and
maintained on a 12-h/12-h day/night cycle. Diabetic BB rats were maintained
on once-daily protamine zinc insulin, with doses based on body weight, 9:00
A.M. glucose, and protocol. The animal care and experimental protocols were
reviewed and approved by the Yale Institutional Animal Care and Use
Committee.
Surgery. One week before each study, all animals were anesthetized with an
intraperitoneal injection (1 ml/kg) of a mixture of xylazine (20 mg/ml AnaSed;
Lloyd Laboratories, Shenandoah, IA) and ketamine (100 mg/ml Ketaset;
Aveco, Fort Dodge, IA) in a ratio of 1:2 (vol:vol), before undergoing vascular
surgery for the implantation of vascular catheters in a carotid artery and
jugular vein. In some rodents, after this procedure, microinjection guide
cannulas were bilaterally inserted into the VMH (coordinates from bregma:
antero-posterior 2.6 mm, medio-lateral 3.8 mm, and dorso-ventral 8.3
mm at an angle of 20°), as described previously (34).
Recurrent hypoglycemia protocol. In these studies, rats received an
intraperitoneal injection of human regular insulin (Eli Lilly, Indianapolis, IN)
at a dose of 10 units/kg given once daily for the 3 consecutive days before the
glucose clamp study. Each episode of hypoglycemia (tail vein blood glucose
1.7–2.2 mmol/l [30–40 mg/dl]) lasted for 3 h, after which the rats were given
free access to food and intraperitoneal dextrose, if required. Any rats
experiencing a seizure were excluded and did not undergo a subsequent
clamp study. The model of recurrent hypoglycemia used in our laboratory has
been previously reported in detail and has been shown to induce suppression
of epinephrine responses to subsequent hypoglycemia (37).
KCOs. This study used intravenous delivery of the SUR-1–selective KCO
NN414 (Novo Nordisk A/S, Malvo, Denmark) (38). NN414 was prepared in 1.5
mg m
1 artiﬁcial extracellular ﬂuid (aECF) for systemic delivery. In all
studies, NN414 was delivered systemically 30 min before the induction of
hypoglycemia.
Microinjection. On the morning of the study, 26-gauge microinjection
needles, designed to extend 1 mm beyond the tip of the guide cannula
(Plastics One, Roanoke, VA), were inserted bilaterally to the VMH. Rats were
then microinjected over 2.5 min (0.1 l/min) with either glibenclamide (12.4
ng dissolved in aECF and 0.5% DMSO or control [aECF with 0.5% DMSO])
using a CMA-102 infusion pump (CMA Microdialysis, North Chelmsford, MA)
(34). Microinjection occurred immediately before the hyperinsulinemic-hypo-
glycemic clamp study as detailed below. At the end of the study, the rats were
killed, and probe position was conﬁrmed in all rats.
Infusion protocol. In all experiments, the same hyperinsulinemic-hypogly-
cemic clamp infusion protocol was used. Overnight-fasted rats had their
vascular catheters opened and were then allowed to settle over 90 min.
Thereafter, a hyperinsulinemic-hypoglycemic clamp technique as adapted for
the rat (6) was initiated. Brieﬂy, at time  0, a 90-min 20 mU  kg
1  min
1
infusion of human regular insulin (Eli Lilly) was started, and the plasma
glucose was allowed to fall to 50 mg/dl (2.8 mmol/l), where it was
maintained for 90 min using a variable rate 20% dextrose infusion (based on
frequent [5 min] plasma glucose determinations). Samples for measurement
of the hormones epinephrine, norepinephrine, glucagon, insulin, and C-
peptide were taken at 30, 0, 60, and 90 min.
Analytical procedures. Plasma glucose was measured by the glucose
oxidase method (Beckman, Fullerton, CA). Catecholamine analysis was
performed by high-performance liquid chromatography using electrochemical
detection (ESA, Acton, MA); plasma insulin and glucagon were measured by
radioimmunoassay (Linco, St. Charles, MO). All data are expressed as the
means  SE and were compared using Student’s two-tailed t test. (Prism 4.0;
GraphPad Software, San Diego, CA).
RESULTS
SUR-1 KCO delivery ampliﬁes the epinephrine
response to hypoglycemia in a dose-dependent manner.
Overnight-fasted rats were given intravenous bolus injec-
tions of NN414 in doses of 6, 0.6, and 0.06 mg/kg or vehicle
30 min before performing a hypoglycemic clamp study
(n  6–10 rats in each group). Additional studies were
performed with 0.006 mg/kg NN414 (n  4), but these data
did not differ signiﬁcantly from the control studies (data
not shown). Basal (t  30 min), after NN414 injection
(t  0 min), and hypoglycemia (t  90 min) levels of
glucose, C-peptide, and insulin are shown in Table 1. Of
TABLE 1
Effect of different intravenous doses of the SUR-1–selective KCO, NN414, on glucose, insulin, and C-peptide under basal and
hyperinsulinemic-hypoglycemic conditions







n 8 6 10 8
Glucose (mg/dl) Basal 119  4 120  6 126  4 122  4
After injection 111  5 115  4 125  4 115  6
Hypoglycemia 46  15 1  1* 52  2* 41  2
Insulin (pmol/l) Basal 491  107 322  68 589  213 519  130
After injection 480  95 285  62 346  105 451  108
Hypoglycemia 3,860  237 4,009  583 3,409  611 4,520  550
C-peptide (pmol/l) Basal 360  51 477  65 611  47 308  53
After injection 271  38 400  40 426  57 75  10†
Hypoglycemia 49  24 5  25 0  24 1  4
*P  0.05 vs. control; †P  0.05 after injection vs. baseline.
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signiﬁcant fall in C-peptide before initiation of the hypo-
glycemic clamp study (308  53 to 75  16 pmol/l; P 
0.05). In addition, mean plasma glucose achieved during
the clamp procedure was slightly but signiﬁcantly higher
in those rats that had been given 0.6 and 0.06 mg/kg
NN414.
During the basal period, mean counterregulatory hor-
mone levels did not differ between groups and were not
affected by injection of NN414 or control (data not
shown). Hypoglycemia induced signiﬁcant rises in all
counterregulatory hormones in both control and NN414
groups, with the exception of high-dose NN414, in which
glucagon failed to rise during hypoglycemia, despite the
marked reduction in C-peptide (Fig. 1A). In contrast,
NN414 had a marked and signiﬁcant effect on plasma
epinephrine during hypoglycemia (Fig. 1B). NN414 given
at 0.6 mg/kg produced an 108% increase in the peak
plasma epinephrine over the control group. The rise in
plasma norepinephrine (Fig. 1C) was substantially less
than the rise in epinephrine, and peak levels were lower in
rats treated with 0.6 and 6 mg/kg NN414. However, the
overall glucose counterregulatory response was signiﬁ-
cantly ampliﬁed with NN414, with all doses resulting in a
clear reduction in the amount of exogenous glucose
(glucose infusion rate [GIR]; Fig. 1D) required to maintain
the hypoglycemic clamp. After 0.6 mg/kg NN414, this
represented an 80% reduction in the GIR.
To explore the utility of the nonselective KCO diazox-
ide, an identical hyperinsulinemic hypoglycemia study was
performed in Sprague-Dawley rats. Diazoxide (6 mg/kg;
n  6) delivered systemically signiﬁcantly ampliﬁed the
mean ( SE) peak epinephrine (2,307  342 vs. 1,479 
205 pg/ml, diazoxide vs. control, respectively; P  0.05)
but not the peak norepinephrine (507  89 vs. 539  29
pg/ml; NS) or peak glucagon (354  38 vs. 252  82 ng/l;
P  0.2) response to hypoglycemia. Diazoxide-treated rats
also required less glucose during the hypoglycemic
clamp study (4.9  1.6 vs. 10.5  1.8 mg  kg
1  min
1;
P  0.05). C-peptide levels fell after diazoxide injection
(476  64 to 313  43 pmol/l; P  0.05) and during the
hypoglycemic clamp study (34  6 pmol/l).
Antecedent delivery of SUR-1 KCO ampliﬁes epi-
nephrine response to subsequent hypoglycemia. To
determine whether the SUR-1 KCO NN414 would have a
persisting effect on counterregulatory responses to hypo-
glycemia, chronically catheterized Sprague-Dawley rats
were injected once daily intravenously with 0.6 mg/kg
NN414 (n  7) or vehicle (n  7) for 3 consecutive days.
On day 4, the overnight-fasted rats underwent a hypogly-
cemic clamp study. Mean ( SE) plasma glucose (47  3
vs. 44  3 mg/dl; NS), insulin (4,347  723 vs. 4,876  642
pmol/l; NS) and C-peptide (39  3 vs. 52  11 pmol/l; NS)
during hypoglycemia did not differ between antecedent
control or NN414-injected groups, respectively. However,
during hypoglycemia, antecedent NN414 resulted in an
FIG. 1. Systemic delivery of the SUR-1–selective KCO NN414 ampliﬁes the glucose counterregulatory response to acute hypoglycemia in
nondiabetic rodents. Peak glucagon (A), peak epinephrine (B), peak norepinephrine (C), and GIRs (D) required to maintain the
hypoglycemic clamp are shown for control (f), 0.06 mg/kg NN414 (d), 0.6 mg/kg NN414 (z), and 6 mg/kg NN414 (2) studies. *P < 0.05 vs.
control.
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71% reduction in the GIR required to maintain the
hypoglycemic clamp (Fig. 2A–D).
VMH KATP channel blockade reverses the action of
systemic SUR-1 KCO. To determine whether the sys-
temic effects of the KCO NN414 were potentially mediated
through an action on the VMH, a key glucose-sensing
region, rats were systemically administered with 0.6 mg/kg
NN414 30 min before performing a hyperinsulinemic-
hypoglycemic clamp study as above. In addition, 5 min
before the start of the clamp, the rats were bilaterally
microinjected to the VMH with the KATP channel blocker,
glibenclamide (12.4 ng in 0.25 l; n  10), or control
solution (vehicle; n  11). Mean plasma glucose, insulin,
and C-peptide did not differ between groups under basal or
hypoglycemic conditions (data not shown) nor did basal
levels of the counterregulatory hormones (Fig. 3A–C). In
control studies, systemic NN414 combined with VMH-
vehicle microinjection produced a similar stimulus to
epinephrine and glucagon as that seen in the dose-re-
sponse studies. This effect was signiﬁcantly blunted when
systemic NN414 (KCO) was combined with VMH-gliben-
clamide (KATP channel closer) (Fig. 3A–C). VMH-gliben-
clamide resulted in a 52% reduction in peak plasma
epinephrine (4,287  807 vs. 2,074  316 pg/medio-lateral;
control vs. glibenclamide, respectively; P  0.05) and a
90% increase in mean GIR during hypoglycemia (4.2  1.0
vs. 8.0  1.2 mg  kg
1  min
1, respectively; P  0.05). As
in the previous studies, no effect was seen on peak
glucagon (290  48 vs. 321  51 ng/l; NS) or norepineph-
rine (546  55 vs. 573  122 pg/ml; NS).
Systemic SUR-1 KCO delivery ampliﬁes the epineph-
rine response to hypoglycemia in nondiabetic and
diabetic BB rats exposed to prior hypoglycemia. To
determine whether NN414, given systemically, would im-
prove the counterregulatory responses to hypoglycemia in
a rodent model of hypoglycemia-associated autonomic
failure (HAAF), hyperinsulinemic-hypoglycemic clamp
studies were performed in nondiabetic rodents who had
been exposed to three consecutive, once-daily episodes of
10 mU/kg insulin-induced hypoglycemia. We have previ-
ously reported that this model induces defective counter-
regulatory responses to subsequent hypoglycemia (35,37).
As in the previous studies, rats received 0.6 mg/kg NN414
or vehicle delivered intravenously 30 min before the clamp
procedure. Basal levels of glucose, insulin, and counter-
regulatory hormones did not differ between groups nor did
levels of glucose and insulin during the clamp procedure.
Plasma C-peptide fell in both groups from baseline values
of 218  45 and 264  39 to 34  6 and 28  4 pmol/l
(control vs. NN414, respectively; NS). Consistent with the
earlier studies, no effect of NN414 was seen on peak
plasma glucagon (Fig. 4A), whereas the peak epinephrine
response during the subsequent hypoglycemic challenge
was increased by 114% (Fig. 4B; P  0.05). The increased
glucose counterregulatory response was reﬂected in a 70%
reduction in the GIR required to maintain the hypoglyce-
mic clamp (Fig. 4D; P  0.01).
Subsequently, we examined the effect of systemic
NN414 in diabetic BB rats, a rodent model of type 1
diabetes. The diabetic BB rats were also subjected to 3-day













































































FIG. 2. Antecedent delivery of SUR-1 KCO ampliﬁes epinephrine response to subsequent hypoglycemia. Graphs show plasma glucose (A), plasma
glucagon (B), plasma epinephrine (C), and GIR (D) during hyperinsulinemic hypoglycemia in rats injected once daily on 3 prior consecutive days
with either control (E, ) or 0.6 mg kg
1 NN414 (F, f). Values are shown as means  SE. *P < 0.05.
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lin, and counterregulatory hormones did not differ be-
tween groups nor did levels of glucose and insulin during
the clamp procedure. As expected, plasma C-peptide was
low under basal (42  10 and 36  3p m o ll
1) and
hypoglycemic (36  1 and 29  3 pmol/l) conditions and
did not differ between groups (control [n  6] vs. NN414
[n  6], respectively). In the diabetic BB rats, no signiﬁ-
cant rise in plasma glucagon from baseline was seen
during hypoglycemia in either group, and peak plasma
glucagon during hypoglycemia also did not differ between
groups (Fig. 5A). However, as in the nondiabetic rats,
systemic NN414 produced a marked stimulus to epineph-
rine secretion (200% increase; Fig. 5B; P  0.05), al-
though absolute epinephrine levels remained lower than
those seen in the nondiabetic rats. In addition, NN414
signiﬁcantly ampliﬁed the norepinephrine response during
hypoglycemia (Fig. 5C; P  0.05), the overall effect being
to reduce GIR by 60% (Fig. 5D; P  0.01).
DISCUSSION
In the present study, systemically delivered SUR-1–selec-
tive KCO was shown to amplify the glucose counterregu-
latory response to acute hypoglycemia in normal and
recurrently hypoglycemic nondiabetic rats and in diabetic
BB rats exposed to recurrent hypoglycemia (a rodent
model of type 1 diabetes with markedly impaired glucose
counterregulation). Moreover, the SUR-1–selective KCO
was effective when given acutely or when delivered for 3
consecutive days before the hyperinsulinemic-hypoglyce-
mic clamp study. Taken together, these studies in the rat
suggest that SUR-1–selective KCOs may have therapeutic
potential for the treatment of HAAF in type 1 diabetic
humans.
The KATP channel consists of pore-forming Kir6.x sub-
units that associate with different types of regulatory
sulfonylurea receptor subunits: SUR-1, SUR-2A, and SUR-
2B. SUR-2 channels are predominantly expressed in car-
diac/skeletal muscle (SUR-2A) and vascular smooth
muscle (SUR-2B) (39), activation of which can cause
vasodilation and effect cardiac muscle contractility. Dia-
zoxide activates both SUR-1 and SUR-2B regulatory sub-
units. When delivered directly to the VMH, diazoxide can
amplify the counterregulatory response to hypoglycemia
(35), and in the current study, when given systemically at
a dose of 6 mg/kg, diazoxide can also amplify the counter-
regulatory response (the higher dose required consistent
with the reduced potency of diazoxide to activate SUR-1
compared with NN414 [38]). However, through its action
on the SUR-2B subunit of the KATP channel, the use of
diazoxide is limited by its potential to cause vasodilation,
reﬂex tachycardia, and hirsuitism (also thought to be
SUR2 mediated). The current studies used a compound,
NN414, developed by Novo Nordisk, as a selective SUR-1
KCO. In vitro studies have shown that NN414 is highly
selective for the Kir6.2/SUR-1 channel, with no signiﬁcant
activation of SUR-2A and -2B channels (38). NN414, even
at high doses, has been shown to have no effect on blood
pressure (40). Thus, for an effective long-term therapy for
individuals with type 1 diabetes, a SUR-1–selective agent is
liable to be both more effective in its action on glucose
sensing and less likely to be associated with these adverse
effects.
Our ﬁndings contrast with those of Raju and Cryer (41),
who examined the effect of oral diazoxide (6 mg/kg) on the
counterregulatory responses to hypoglycemia in 14 nondi-
abetic humans. Diazoxide, given orally, suppressed basal
C-peptide and suppressed the glucagon response to hypo-
glycemia induced 2 h later while having no effect on
epinephrine, norepinephrine, or neurogenic symptoms
(41). Similarly, Bingham et al. (42) reported no effect of
oral diazoxide (5 mg/kg) on the hormonal counterregula-
tory response in 10 nondiabetic humans. In our rodent
study, diazoxide given intravenously 30 min before hypo-
glycemia also suppressed C-peptide but resulted in an
ampliﬁed epinephrine response during hypoglycemia. The
glucagon response was also increased but not signiﬁcantly
so. These differences may reﬂect species differences in
Kir6.2/SUR-1 channel expression and function, and in
addition, the higher systemic diazoxide levels that were
probably achieved in the rodent may have induced a
degree of hypotension (not measured in the present study)
that may have contributed to the epinephrine response.
However, this would not explain the NN414 ﬁndings. Fur-





























































FIG. 3. Local VMH KATP channel blockade blunts the effect of systemic
KCOs to amplify the glucose counterregulatory response to hypoglyce-
mia. Plasma glucagon (A), plasma epinephrine (B), and GIR (C) during
hyperinsulinemic hypoglycemia in rats pretreated with systemic NN414
and with VMH microinjection of glibenclamide (F, f) or systemic
NN414 and VMH microinjection of vehicle (E, ). Values are shown as
means  SE. *P < 0.005 vs. control study.
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during hypoglycemia (data not shown). The consistent effect
of NN414 to amplify the epinephrine counterregulatory re-
sponse suggests that higher systemic levels of diazoxide may
be necessary to induce a SUR-1–mediated action on the



















































































FIG. 4. Systemic delivery of a SUR-1–selective KCO (0.6 mg kg
1 NN414) ampliﬁed the glucose counterregulatory response to acute hypoglycemia
in nondiabetic rodents with defective counterregulation after exposure to three episodes of antecedent recurrent hypoglycemia (RH). Peak
glucagon (A), peak epinephrine (B), peak norepinephrine (C), and GIRs (D) during subsequent hyperinsulinemic hypoglycemia are shown. ,




















































































FIG. 5. Systemic delivery of a SUR-1–selective KCO (0.6 mg kg
1 NN414) ampliﬁed the glucose counterregulatory response to acute hypoglycemia
in diabetic rats (BB) with defective counterregulation. Peak glucagon (A), peak epinephrine (B), peak norepinephrine (C), and GIRs (D) during
subsequent hyperinsulinemic hypoglycemia. , BB control rats; f, NN414-treated BB rats. Values are shown as means  SE. *P < 0.005 vs. control
study.
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markedly suppressed glucagon secretion during hypogly-
cemia. Before induction of the hypoglycemic clamp,
plasma C-peptide was also more markedly suppressed by
high-dose NN414. This latter ﬁnding is consistent with the
intraislet insulin hypothesis, in which defective glucagon
secretion during hypoglycemia is thought to arise through
a failure of intraislet insulin levels to fall (41). Alterna-
tively, it may represent a direct action of NN414 on KATP
channels in the pancreatic 	-cells. It has been shown in
	-cells isolated from SUR-1
/ mice, but not wild-type
mice, that both tolbutamide and glucose fail to produce
membrane depolarization and that diazoxide reduces glu-
cagon secretion to the same extent as an elevation of
glucose (43). This effect might arise from the distinct
electrophysiological properties of 	-cells.
It was also notable that norepinephrine responses dur-
ing hypoglycemia did not parallel those of epinephrine.
During hypoglycemia, systemic norepinephrine has not
proven discriminatory in previous clamp studies in ro-
dents by our group (34,35). Norepinephrine is released
primarily from sympathetic nerve terminals, and so, sys-
temic levels provide only a weak index of local sympa-
thetic neural activity. Plasma norepinephrine is also both
lower than epinephrine (10–25%) and a less potent
agonist of adrenergic receptors, so small differences be-
tween groups in systemic levels are not informative. It was
also of note that the absolute effect of NN414 was less in
diabetic BB rats than in nondiabetic rats. This suggests
that additional mechanisms, not reversible through KCO
therapy, may contribute to defective counterregulation in
diabetes.
It is interesting to speculate on where the systemically
delivered KCO might act. Although the Kir6.x pore-forming
unit is widely expressed in the body, the expression of
SUR-1 is predominantly limited to brain and pancreas (44).
Within the brain, SUR-1 and Kir6.x are expressed both in
regions known to be involved in glucose sensing and in
other brain regions (45). Glucose-sensing neurons in the
VMH are known to express SUR-1 (30). Our data demon-
strating that the action of systemic NN414 could be
reversed after the direct application of a KATP channel
blocker to the VMH suggest this is one potential site that
mediates the effect of NN414. That being said, it is also
possible that the changes seen were the net result of KATP
channel opening at a different site and an independent
action of KATP channel closure in the VMH. NN414, if
acting centrally, could equally be acting on glucose-sens-
ing neurons in other brain regions such as the hindbrain.
Sulfonylurea-like compounds are not generally thought to
cross the blood-brain barrier (46), although recent studies
of KCOs in ischemic preconditioning in the brain provide
some evidence that they might act centrally (47). Unfortu-
nately, a radiolabeled form of NN414 is not available to
directly test this question. Another possibility is that
NN414 is interacting with portal-mesenteric vein (PMV)
glucose sensors. PMV glucose sensors play a role in the
modulation of counterregulatory responses to hypoglyce-
mia. However, PMV glucose sensors are thought to play a
greater role in slow-fall rather than the rapid induction of
hypoglycemia induced in the present study (48), and a role
for SUR-1 in these sensors has not been established.
Another peripheral glucose sensor is located in the carotid
body, but dogs with carotid body resections showed
blunted glucagon and cortisol secretion during hypoglyce-
mia, with epinephrine and norepinephrine release being
unaffected (49). Finally, SUR-1 and Kir6.2 are coexpressed
with glucagon-like peptide 1 (GLP-1) in intestinal L- and
K-cells (50), which raises the possibility of an indirect
action through altered GLP-1 secretion. However, we have
previously shown in human subjects that glucose ingestion
while hypoglycemia is maintained leads to an ampliﬁca-
tion of the epinephrine response (51), which would sug-
gest that KATP closure, rather than opening, within L-cells
mediates this effect. Moreover, GLP-1 secretion is liable to
be minimal during hypoglycemia.
One other notable ﬁnding in the present study was that
3 days of NN414 given as a single intravenous bolus
resulted in an ampliﬁed epinephrine response to a subse-
quent controlled hypoglycemic challenge. The ability of a
compound to amplify counterregulatory responses to a
subsequent episode of hypoglycemia and not just when
given during the hypoglycemic episode would be impor-
tant for type 1 diabetic individuals in whom hypoglycemia
does usually occur at predictable times. Why this effect
should occur after 3 days of NN414 therapy is unknown.
NN414 given to human subjects at a similar dose (0.625
mg/kg) has a half-life of only 1.2 h (40), and so it seems
unlikely to represent a persisting direct action on the
Kir6.2/SUR-1 channel. This ﬁnding therefore raises the
possibility that NN414 could through secondary effects
render the glucose-sensing pathway more sensitive to a
subsequent hypoglycemic challenge.
In summary, in the current study, we have been able to
demonstrate in a variety of rodent models that the SUR-
1/Kir6.2–selective KCO when given systemically is able to
amplify epinephrine responses to hypoglycemia. These
studies provide the ﬁrst evidence of a potential therapeutic
intervention for HAAF in type 1 diabetes. The dose of
NN414 that we used in these rodent studies compares with
that of trials in human subjects assessing pharmacokinet-
ics after single-dose NN414 (0.625–12.5 mg/kg) (40); how-
ever, no human studies using this compound during
hypoglycemia have as yet been performed. Future studies
in rodent models designed to establish the best strategies
for delivering these agents and in human subjects to
validate the rodent data are now required.
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